NeuroOne Reports Impressive Third Quarter Financial Results
Completed an oversubscribed $8.2 million capital raise, ensuring funding through at least the fiscal year 2026.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), a pioneering medical technology firm focused on revolutionizing the surgical diagnosis and treatment of neurological conditions, has recently disclosed its financial performance for the third quarter of fiscal year 2025, concluding on June 30, 2025.
Key Highlights of the Company
In this quarter, NeuroOne achieved significant milestones:
- Product revenue surged by 105%, reaching $1.7 million compared to $0.8 million in the same quarter last year.
- Gross margin for products expanded notably to 53.9%, up from 34.1% reported in the previous year.
- Operating expenses saw a reduction of 9%, decreasing to $2.8 million from $3.1 million a year prior.
- The company successfully wrapped up an oversubscribed capital raise amounting to $8.2 million from institutional investors.
- A key milestone was reached when the first OneRF® Ablation System patient celebrated over a year of seizure freedom, alongside positive outcomes for other patients.
- NeuroOne filed an FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablation System, with a response anticipated soon.
- The company secured its first order for its sEEG-based drug delivery system, currently under development, representing a new market vertical.
- Received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO), affirming the issuance of a critical patent that addresses the manufacturing of its neural and spinal cord stimulation electrodes, bolstering its competitive edge.
- Expanded its management team by welcoming Dr. Parag Patil as Chief Medical Advisor and other professionals to guide its growth.
Management Insights
CEO Dave Rosa expressed enthusiasm regarding the company’s accelerated growth and operational advancements. He emphasized that the dramatic revenue boost and profitability trajectory demonstrates the effectiveness of their technology in providing substantial quality-of-life improvements for patients battling neurological disorders, particularly those experiencing debilitating seizures.
Rosa noted that as they continue scaling the OneRF® Ablation system's market presence, the positive results from patients not only validate their technology but also reflect their commitment to enhancing quality of life through innovative medical solutions.
NeuroOne is actively pursuing market expansion through leveraging their already established electrode technology. Following the recent FDA submission for the trigeminal nerve ablation system, they anticipate revenue generation in this area within the calendar year. Furthermore, the company proactively initiated the application process for ISO 13485 certification to facilitate entry into international markets, which could unlock further expansion opportunities.
Operational Achievements
OneRF® Ablation System:
- The first patient reported one year of seizure freedom after treatment.
- Additional patients recorded significant improvements in seizure control.
- NeuroOne engaged with Zimmer Biomet for advanced training to optimize treatment protocols.
- Product showcased at the American Association of Neurological Surgeons (AANS) conference in April 2025.
- Plans for a registry to track clinical outcomes are underway.
OneRF® Trigeminal Nerve Ablation System:
- FDA submission filed in April 2025, ahead of projections.
- Expected feedback from the FDA shortly could catalyze market entry in 2025.
OneRF® BVNA Nerve Ablation System:
- The program focusing on lower back pain treatment through ablation has commenced development.
- An advisory board of experts is guiding this initiative.
sEEG-Based Drug Delivery Program:
- The company has received its first order from a major biopharmaceutical firm to use its drug delivery technology in research.
- Animal studies validate the technology's feasibility for small animal research.
International Market Initiatives:
- ISO 13485 certification efforts have begun, signaling future sales opportunities outside the U.S.
Financial Performance Overview
NeuroOne’s product revenue soared to $1.7 million for the third quarter of fiscal 2025, a striking increase from $0.8 million in the same period of the previous year. The first nine months of fiscal 2025 reflected an impressive total product revenue of $6.4 million, a 100% increase compared to $3.2 million in fiscal 2024.
The gross profit from product sales reached $0.9 million, signifying a gross profit margin of 53.9%, compared to 34.1% previously reported. Total operating expenses fell to $2.8 million, with reductions noted across both R&D and SG&A expenses. The company realized a net loss of $1.5 million for the third quarter, showcasing an improvement from a loss of $2.8 million in the prior year's quarter.
As of the end of June 2025, NeuroOne boasts cash reserves of $8.0 million, significantly up from $1.5 million a year before, demonstrating a solid financial footing.
Outlook for Fiscal 2025
NeuroOne maintains an optimistic outlook for the fiscal year projecting product revenue between $8.0 million and $10.0 million, which represents between 132% and 190% growth year-over-year. The expected product gross margin for the year is set to improve further between 50% and 53%.
Frequently Asked Questions
What significant financial results did NeuroOne report for Q3?
NeuroOne reported a revenue increase of 105% year-over-year, reaching $1.7 million with a gross margin of 53.9%.
What steps are being taken for international expansion?
The company is pursuing ISO 13485 certification to facilitate entry into international markets, potentially opening new revenue streams.
How is the OneRF® Ablation System performing post-launch?
Patients treated with the OneRF® system have reported significant improvements, including one patient achieving over a year of seizure freedom.
What was the outcome of the recent capital raise?
NeuroOne successfully completed an oversubscribed capital raise of $8.2 million, enhancing their financial stability for upcoming initiatives.
What is the future revenue guidance for NeuroOne in fiscal 2025?
NeuroOne expects product revenue to fall between $8.0 million and $10.0 million, indicating significant growth potential compared to fiscal 2024.
